Hindustan Bio Sciences Ltd (HINDBIO) — shareholding pattern, promoter holding, financials and share price
About Hindustan Bio Sciences Ltd (HINDBIO)
Hindustan Bio Sciences Ltd operates in the Software Products industry, within the Information Technology sector. It trades on the NSE as HINDBIO and on the BSE under scrip code 532041. Its ISIN is INE597C01021.
Incorporated in 2000, Hindustan Biosciences Ltd manufactures & sells pharmaceutical products. [1]
Hindustan Bio Science Ltd is primarily engaged in manufacturing and selling pharmaceutical products, specifically in pharmaceuticals and biotechnology sectors.
The company has a diverse operational scope, transitioning from bulk drug sourcing to manufacturing finished dosage forms of pharmaceuticals.
Listed peers in Software Products: Svam Software Ltd, First Fintec Ltd, Nihar Info Global Ltd, Virgo Global Ltd, Omni Axs Software Ltd, Pagaria Energy Ltd.
Valuation & Returns
10 Jul 2026At ₹7.2 a share on 10 Jul 2026, Hindustan Bio Sciences Ltd (HINDBIO) was valued at a price-to-book of 8.16x on a book value of ₹0.88 per share as of Mar 2025. Solomo computes return on equity of -9.95% and return on capital employed of -2.64% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- Industry P/E
- 17.23x
- P/B
- 8.16x
- EPS (TTM)
- ₹-0.09
- Book value / share
- ₹0.88
- ROE
- -9.95%
- ROCE
- -2.64%
- ROA
- -2.63%
- Debt / equity
- 2.77x
- Dividend yield
- 0%
- EBITDA margin
- -8.57%
- 52-week range
- ₹6.97 – ₹7.34
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Hindustan Bio Sciences Ltd (HINDBIO) reported revenue of ₹0.74 crore, net profit of ₹-0.08 crore and earnings per share of ₹-0.08. That compares with revenue of ₹0.81 crore and net profit of ₹0.1 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, net profit ₹-0.12 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 0.43 | 0.92 | 1.05 | 0.81 | 0.74 |
| Net profit (₹ cr) | -0.52 | -0.04 | 0.06 | 0.1 | -0.08 |
| EPS (₹) | -0.51 | -0.04 | 0.06 | 0.1 | -0.08 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | -4.75% | -15.99% | 23.61% | -22.86% |
| Profit growth | - | 4.48% | - | 66.67% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 12.19% of Hindustan Bio Sciences Ltd (HINDBIO) (unchanged from the previous quarter). Market capitalisation was ₹7 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: BOSCO ARMANDO MENEZES 2.71%, SATYASAI KOLLI 2.59%, HUF 2.57%, EMILY BOSCO MENEZES 2.49%, MADHUSUDAN RAO POLINENI 1.61%, CHINTALAPATI DEEPIKA 1.37%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 12.19% | - | - | - | 87.81% |
| Mar 2026 | 12.19% | - | - | - | 87.81% |
| Dec 2025 | 12.19% | - | - | - | 87.81% |
| Sep 2025 | 12.19% | - | - | - | 87.81% |
| Jun 2025 | 12.19% | - | - | - | 87.81% |
| Mar 2025 | 12.19% | - | - | - | 87.81% |
| Dec 2024 | 12.19% | - | - | - | 87.81% |
| Sep 2024 | 12.19% | - | - | - | 87.81% |